Advertisement

Topics

Pfizer Ophthalmics Company Profile

02:57 EDT 24th September 2017 | BioPortfolio

Pfizer Ophthalmics, a division of Pfizer Inc, is committed to preserving sight and eliminating preventable blindness. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them. Its current product line includes the most prescribed treatment to lower elevated eye pressure in patients with ocular hypertension (abnormally high eye pressure) or open-angle glaucoma. Pfizer Ophthalmics also markets a treatment for neovascular age related macular degeneration outside the U.S.


News Articles [834 Associated News Articles listed on BioPortfolio]

Allegro Ophthalmics raises $10.7mm

Allegro Ophthalmics LLC raised $10.7mm in an undisclosed financing round. According to the Form D, 17 investors participated.

Pfizer Announces First Partners of Pfizer Healthcare Hub: London

Pfizer Ltd has announced that Echo, Cera and GiveVision will form the first cohort of healthtech start-ups to be supported by the Pfizer Healthcare Hub: London.The three start-ups will work with Pfi...

Allegro Ophthalmics receives $10.7 million in private financing

Allegro Ophthalmics announced it has secured $10.7 million in a private round of equity financing. The additional capital will allow the company to complete several phase 2 clinical trials and help pr...

Pfizer-Aktie moderat im Minus

Anteilseigner von Pfizer verzeichnen gegenwärtig einen Kursabschlag im Depot: Der Kursverlust beträgt -0,4% im Vergleich zum Vortages-Schlusskurs. Damit entwickelt sich Pfizer schlechter als der D...

Pfizer Obtains Exclusive Commercialization Rights In Europe To CRESEMBA

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE)and Basilea Pharmaceutica Ltd. announced that they have completed the licensing agreement whereby Pfizer has obtained the exclusive commercialization rig...

Kann die Pfizer-Aktie bald wieder überzeugen?

Aktuell steht bei der Aktie von Pfizer ein Kursverlust im Vergleich zum Freitagswert in Höhe von -0,3% auf dem Kursticker. Damit bewegt sich die Pfizer-Aktie fast im Gleichschritt mit dem Vergleich.....

John Snisarenko named Shire’s group vice president, head of ophthalmics

Shire has named John Snisarenko as its new group vice president and head of ophthalmics in the Unites States, according to company correspondence. Snisarenko, who most recently served as vice presiden...

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK (Reuters) - U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder...

Drugs and Medications [103 Associated Drugs and Medications listed on BioPortfolio]

Preparation h [Pfizer Consumer Healthcare]

Preparation H Suppositories(cocoa butter and phenylephrine HCl)

Chapstick overnight [Pfizer Consumer Healthcare]

ChapStick Overnight Lip Treatment (dimethicone)

Preparation h [Pfizer Consumer Healthcare]

Preparation H Hemorrhoidal Ointment (mineral oil, petrolatum and phenylephrine HCl)

Anbesol cold sore therapy [Pfizer Consumer Healthcare]

Anbesol Cold Sore Therapy(allantoin, benzocaine, camphor, and white petrolatum)

Chapstick lipshield 365 [Pfizer Consumer Healthcare]

Chapstick LipShield 365(avobenzone, dimethicone, homosalate, octinoxate, octisalate, and oxybenzone)

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Avelumab: First Global Approval.

Avelumab (Bavencio(®)) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the biopharmaceutical division of Merck KGaA, Da...

Letter--The Authors Respond.

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or int...

Discovery of Clinical Candidate 1-{(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-ylmethoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.

Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a P...

Bivalent rLP2086 (Trumenba®): Development of a well-characterized vaccine through commercialization.

The phrase "Process is the Product" is often applied to biologics, including multicomponent vaccines composed of complex components that evade complete characterization. Vaccine production processes m...

Antibody persistence up to five years after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.

Long-term protection against meningococcal disease relies on antibody persistence after vaccination. We report antibody persistence up to 5 years after vaccination in adolescents who received a singl...

Clinical Trials [79 Associated Clinical Trials listed on BioPortfolio]

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US ...

A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects

The primary objective of the study is to determine bioequivalence of 50 mg (2x25 mg) Artesunate Sachet (Pfizer) versus 50 mg (1x50 mg) tablet, Arsuamoon® (Guilin China) which is the World...

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU a...

A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects

The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions

An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. ...

Companies [115 Associated Companies listed on BioPortfolio]

Pfizer Ophthalmics

Pfizer Ophthalmics, a division of Pfizer Inc, is committed to preserving sight and eliminating preventable blindness. Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalm...

Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the ...

The Pfizer Foundation

The Pfizer Foundation is a charitable organization established by Pfizer Inc. The Foundation is a separate and independent tax-exempt organization. The Foundation’s mission i...

Renata Limited

Historical High-Lights: Founded in 1972 as a subsidiary of Pfizer Inc. Ownership transferred from Pfizer Inc. to local institutions and the general public in 1993. Company name subsequently changed fr...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

More Information about "Pfizer Ophthalmics" on BioPortfolio

We have published hundreds of Pfizer Ophthalmics news stories on BioPortfolio along with dozens of Pfizer Ophthalmics Clinical Trials and PubMed Articles about Pfizer Ophthalmics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pfizer Ophthalmics Companies in our database. You can also find out about relevant Pfizer Ophthalmics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Adempas (riociguat)
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...


Corporate Database Quicklinks



Searches Linking to this Company Record